Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oral Self-Management of Palbociclib (Ibrance®) Using Mobile Technology

NCT04216576 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT04216576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04216576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oral Self-Management of Palbociclib (Ibrance®) Using Mobile Technology
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Not applicable
Overall status
Active, not recruiting
Start date
December 27, 2019
Completion date
December 27, 2026
Enrollment
45 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer